Form 4: Anika Therapeutics Insider McLeod Reports Vesting, Tax Withholdings

Anika Therapeutics' SVP, CAO & Treasurer Ian McLeod reported the vesting of restricted stock units and performance-based phantom units, alongside associated tax withholdings.

Summary

• Ian McLeod, SVP, CAO & Treasurer of Anika Therapeutics, Inc. (ANIK), reported transactions related to his equity holdings.
• On March 14, 2026, 3,774 Restricted Stock Units (RSUs) and 1,161 Performance-based Phantom RSUs (PSUs) vested, resulting in the acquisition of 4,935 shares of common stock.
• On the same date, 1,449 shares of common stock were disposed of by the Issuer to satisfy tax withholding obligations at a price of $14.2 per share.
• On March 15, 2026, an additional 2,658 RSUs vested, leading to the acquisition of 2,658 shares of common stock.
• On March 15, 2026, 781 shares of common stock were disposed of by the Issuer for tax withholding purposes, also at a price of $14.2 per share.
• Following these transactions, McLeod's direct beneficial ownership of Anika Therapeutics common stock is 24,107 shares.
• He also holds 7,550 unvested RSUs from a March 14, 2025 grant and 2,659 unvested RSUs from a March 15, 2024 grant.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a routine insider transaction report reflecting the scheduled vesting of equity awards and associated tax withholdings, which is a standard component of executive compensation.

Positives

• Vesting of 3,774 Restricted Stock Units (RSUs) on March 14, 2026, representing the first installment of a 2025 grant.
• Vesting of 1,161 Performance-based Phantom RSUs (PSUs) on March 14, 2026, representing the first installment of a 2025 grant, contingent on performance targets.
• Vesting of 2,658 Restricted Stock Units (RSUs) on March 15, 2026, representing the second installment of a 2024 grant.
• Increased direct beneficial ownership of common stock to 24,107 shares after the vesting events.

Negatives

• Disposition of 1,449 shares of common stock on March 14, 2026, to cover tax withholding obligations related to vested RSUs and PSUs.
• Disposition of 781 shares of common stock on March 15, 2026, to cover tax withholding obligations related to vested RSUs.
• The tax withholdings reduced the net shares received from vesting.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that Form 4 filings provide transparency into insider trading activities, which can sometimes signal management's confidence or concerns about the company's future prospects. This specific filing details routine vesting and tax-related dispositions, which are common for executive compensation plans.

Stakeholder Impact

• Shareholders: Provides transparency into executive compensation and changes in insider ownership, which can influence investor confidence.
• Employees: Reflects the company's executive compensation structure, potentially impacting morale and retention strategies.

Next Steps

• Future vesting installments for the 11,324 RSUs granted on March 14, 2025 (two more equal annual installments after March 14, 2026).
• Future vesting installment for the 7,976 RSUs granted on March 15, 2024 (one more equal annual installment after March 15, 2026).
• Future vesting installments for the 3,484 PSUs granted on March 14, 2025 (two more installments after March 14, 2026, contingent on performance).

Key Dates

Keywords

Anika Therapeutics, ANIK, Ian McLeod, Form 4, Insider Trading, Restricted Stock Units, RSU, Performance Stock Units, PSU, Stock Vesting, Tax Withholding, Beneficial Ownership